Browsing by Author "Ogun, O."

Now showing 1 - 2 of 2

5 Fluorouracil versus mitomycin-c as adjuncts to conjuctival autograft in preventing pterygium recurrence
(Springer, 2012) Bekibele, C. O.; Ashaye, A.; Olusanya, B.; Baiyeroju, A.; Fasina, O.; Ibrahim, A. O.; Ogun, O.
To compare the efficacy of 5-fluorouracil (5-FU) with mitomycin C (MMC) in preventing pterygium recurrence when used as an adjuvant following pterygium excision with conjunctival autograft. Low-dose MMC combined with conjunctival autograft is an effective treatment for preventing recurrence following pterygium excision, but safety, cost, and availability limit its use in developing countries. There is a paucity of data on the efficacy of 5-FU when used in Africa as an adjuvant to conjunctival autograft following pterygium excision. This is a randomized controlled prospective trial using either 50 mg/ml 5-FU or 0.01% MMC. Eighty eyes of 80 subjects were studied. Forty-six subjects with a mean age 49.8 ± 13.8 years were treated with 5-FU (USD 13.0 per unit), while 34 patients with a mean age 51.9 ± 12.1 years were treated with MMC (USD 20.0 per unit). There was no significant difference in mean age between the two groups (p = 0.48). The ratio of male to female patients in both groups was similar at 0.92:1 for the 5-FU group and 1:1 for the MMC group (p = 0.85). Mean follow-up period was 35.2 ± 29.1 weeks. Recurrence rate in the 5-FU group was 8.7% compared to 11.8% in the MMC group (recurrence risk ratio = 0.71, 95% CI 0.17-3.1, p = 0.7). One patient from the MCtreated group had corneoscleral melting. Other complications were mild and not sight threatening. In the prevention of pterygium recurrence, 5-FU appears to compare favorably with low-dose MMC when used as an adjuvant following pterygium excision and conjunctival autograft. Further studies are required to assess the long-term effect of using 5-FU in such cases.
Role of transcranial colour-coded duplex sonography in stroke management
(West Africa Medical Ultrasound Society, 2015) Olatunji, R. B.; Ogbole, G. I.; Atalabi, O. M.; Adeyinka, A. O.; Lagunju, I.; Oyinlade, A.; Ogun, O.; Owolabi, M.O.; Ogunseyinde, O. A.; Ogunniyi, A.
The development of transcranial colour-coded duplex sonography (TCCS) has resurrected the hope of safe, real time bedside brain imaging beyound childhood. This review article provides an overview of the role of TCCS in the management of patients with stroke. The objective is to stimulate interest in the field of neurosomology as a potential means of improving neurological outcome for stroke patients and a area for stroke research endeavours in Africa. Literature search was done on MEDLINE, Cochrane library, and GoogleScholar database with the following keywords: transcranial colour Doppler, Transcranial duplex sonography,stroke, infarct and haemorrhage. We also identified relevant articles from the references section of studies produced by our literature search. We discussed the roles of TCCS to discriminate ischaemic from haemorrhagic forms; unravel the mechanism of stroke; monitor temporal evolution of stroke and predictors of stroke outcome; and promote better understanding of the epidemiology of stroke. It emerging role as a potent point-of-care imaginf modality for definitive treatment in ischaenic stroke within and outside the hospital setting is also highlighted. Comparison of TCCS with alternative modalities for neuroimaging for stroke patients in Africa is presented vis-a-vis the potential economic relief which widespread adoptionof TCCS may provide. We advocate capacity building for TCCS and suggest some action plans required to achieve safe, cheap, affordable and reliable ultrasound based neuroimaging for stroke patients in resource limited areas of Africa.